Menorrhagia Clinical Trials

Find Menorrhagia Clinical Trials Near You

HMBeacon: A Phase 2, Randomized, Double-blind Study of the Safety, Tolerability, Efficacy, and Pharmacodynamics of Multiple Dose ALN-6400 in Adult and Adolescent Female Patients With Von Willebrand Disease (VWD) and Heavy Menstrual Bleeding (HMB)

Status: Recruiting
Location: See all (21) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacodynamics (PD) of multiple doses of ALN-6400 in adult and adolescent patients with VWD and HMB

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 16
Maximum Age: 45
Healthy Volunteers: f
View:

• Is an adolescent or adult patient with a diagnosis of VWD (including Type 1, Type 2, Type 3, and platelet-type VWD) and HMB for 2 cycles during screening

Locations
United States
California
Clinical Trial Site
NOT_YET_RECRUITING
Orange
Clinical Trial Site
NOT_YET_RECRUITING
San Diego
Clinical Trial Site
NOT_YET_RECRUITING
San Francisco
Florida
Clinical Trial Site
RECRUITING
Miami
Georgia
Clinical Trial Site
NOT_YET_RECRUITING
Augusta
Kentucky
Clinical Trial Site
NOT_YET_RECRUITING
Lexington
North Carolina
Clinical Trial Site
NOT_YET_RECRUITING
Chapel Hill
Ohio
Clinical Trial Site
NOT_YET_RECRUITING
Cleveland
Pennsylvania
Clinical Trial Site
NOT_YET_RECRUITING
Pittsburgh
South Carolina
Clinical Trial Site
NOT_YET_RECRUITING
Charleston
Other Locations
Netherlands
Clinical Trial Site
NOT_YET_RECRUITING
Nijmegen
Clinical Trial Site
NOT_YET_RECRUITING
Utrecht
Sweden
Clinical Trial Site
NOT_YET_RECRUITING
Stockholm
Turkey
Clinical Trial Site
NOT_YET_RECRUITING
Istanbul
Clinical Trial Site
NOT_YET_RECRUITING
Şahinbey
Clinical Trial Site
NOT_YET_RECRUITING
Samsun
United Kingdom
Clinical Trial Site
NOT_YET_RECRUITING
Birmingham
Clinical Trial Site
NOT_YET_RECRUITING
Bradford
Clinical Trial Site
NOT_YET_RECRUITING
London
Clinical Trial Site
NOT_YET_RECRUITING
Oxford
Clinical Trial Site
NOT_YET_RECRUITING
Truro
Contact Information
Primary
Alnylam Clinical Trial Information Line
clinicaltrials@alnylam.com
1-877-ALNYLAM
Backup
Alnylam Clinical Trial Information Line
clinicaltrials@alnylam.com
1-877-256-9526
Time Frame
Start Date: 2026-07-30
Estimated Completion Date: 2029-08-30
Participants
Target number of participants: 24
Treatments
Experimental: ALN-6400 (Treatment Group A)
Participants will be administered multiple doses of ALN-6400.
Experimental: ALN-6400 (Treatment Group B)
Participants will be administered multiple doses of ALN-6400.
Sponsors
Leads: Alnylam Pharmaceuticals

This content was sourced from clinicaltrials.gov